| 货号 | HT073016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | Research Grade Biosimilar |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa-lambda |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G, purified from cell culture supernatant. |
| Accession号 | P15692 & O15123 |
| 状态 | Liquid |
| 保存溶液 | 20mM His,140mM NaCl,pH6.0 |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | Bispecific,RG7716,RO6867461,CAS:1607793-29-2 |
| 背景 | Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
SDS-PAGE for Research Grade Faricimab
Detects Human ANGPT2 in indirect ELISAs.
Detects VEGFA in indirect ELISAs.
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
